Patent ID: 11878000
Assignee: CEDARS-SINAI MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 16:
17. A kit, the kit comprising:
(1) one or more sensitizer compound in a suitable form for delivery, wherein the sensitizer compound is a DZ1-drug amide or ester conjugate comprising a DZ1 residue and a drug residue,
(2) at least one pharmaceutically acceptable carrier, and
(3) instructions for coordinated administration of the sensitizer compound and a tyrosine kinase inhibitor (TKI), wherein the TKI is not conjugated to the sensitizer compound, in a common administration regimen for treatment of a cancer that develops TKI resistance;, wherein the cancer that develops TKI resistance comprises: a cancer that is associated with tyrosine kinase abnormalities, a cancer which overexpresses a tyrosine kinase, and a cancer associated with mutations that lead to EGFR overexpression; wherein the drug forming the drug residue of the sensitizer is selected from the group consisting of a statin drug, a platin-based anti-neoplastic drug, and artemisinin,, and wherein the DZ1 residue is selected from an amide and an ester-linked residue shown in formulae I and II below:, , wherein ˜ represents a point of attachment to the drug residue.